BrainStorm Stem Cell Therapy Treatment Shown To Be More Effective Than Other Current Potential Stem Cell Treatments

NEW YORK & PETACH TIKVAH, Israel--(Business Wire)--
BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult
stem cell technologies and therapeutics, is pleased to announce that the
company`s therapeutic approach for treating neurodegenerative diseases was shown
to be superior to other current potential stem cell treatments.

In a scientific paper published in the Israel Medical Association Journal, Ofer
Sadan, Eldad Melamed and Daniel Offen, from Tel Aviv University, show the
migratory capacity of Neurotrophic Factor Stem Cells (NTF-SC) in animal models
of Parkinson`s disease and Huntington disease. The study demonstrated that in a
rat model for Parkinson`s disease, the efficacy of NTF-SC was superior to that
of mesenchymal stem cells in terms of behavioral, biochemical and histological
indices.

"The results of this study show that the NTF-SC based treatment is efficacious
due to NTF secretion and the stem cell`s migratory capabilities. Since our novel
technology is clinically compatible and safe, the study suggests that in the
future, cell therapy based on the transplantation of NTF-SC derived from
autologous human mesenchymal stem cells should become a preferable option in the
treatment of neurodegenerative diseases," commented Professor Daniel Offen,
Brainstorm`s chief scientific advisor.

"This study demonstrates that Brainstorm`s approach in differentiating adult
mesenchymal stem cells into NTF-SC, will provide the most effective approach for
the treatment of neurodegenerative diseases via the use of stem cells," said
Rami Efrati, CEO of Brainstorm. "As we near clinical trials, the Company and its
scientific team will continue to study how our technology and methodology can be
further utilized with other neurodegenerative diseases."

The complete study and scientific paper can be read on Brainstorm`s website at
http://www.brainstorm-cell.com/_Uploads/47Sadan2009.pdf.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem
cell therapeutic products, derived from autologous (self) bone marrow cells, for
the treatment of neurodegenerative diseases. The patent pending technology is
based on discoveries made by the scientific team led by Professor Eldad Melamed,
former Head of Neurology at Rabin Medical Center, and cell biologist Prof.
Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical
Research Center of Tel-Aviv University. The technology allows for the
differentiation of bone marrow-derived stem cells into functional neurons and
astrocytes, as demonstrated in animal models. The Company holds rights to
develop and commercialize the technology through an exclusive, worldwide
licensing agreement with Ramot at Tel Aviv University Ltd., the technology
transfer company of Tel-Aviv University. The Company's current focus is on ALS,
although its technology has promise for treating several other diseases
including MS, Huntington's disease and stroke.

Safe Harbor Statement

Statements in this announcement other than historical data and information
constitute "forward-looking statements" and involve risks and uncertainties that
could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking statements,
including BrainStorm's ability to complete its equity financing transactions
previously disclosed. The potential risks and uncertainties include, among
others, risks associated with BrainStorm Cell Therapeutics Inc.'s limited
operating history, history of losses and expectation to incur losses for the
foreseeable future; minimal working capital and difficulty raising additional
capital, dependence on its license to Ramot's technology; ability, together with
its licensor, to adequately protect the technology; dependence on key executives
and on its scientific consultants; ability to identify, negotiate and
successfully implement strategic partnering relationships; ability to complete
clinical trials successfully and to obtain required regulatory approvals;
competition with companies, some of which have greater resources and experience
in developing and obtaining regulatory approval for treatments in BrainStorm
Cell Therapeutics Inc.'s market; the limited public trading market for
BrainStorm Cell Therapeutics Inc.'s stock which may never develop into an active
market; and other factors detailed in BrainStorm Cell Therapeutics Inc.'s annual
report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K
and other filings with the Securities and Exchange Commission available at
http://www.sec.gov/ or by request to the Company. The Company does not undertake
any obligation to update forward-looking statements made by us.

BrainStorm Cell Therapeutics
Rami Efrati, CEO, +972-3-9236384
efrati@brainstorm-cell.com

Copyright Business Wire 2009